Company news
Macrogenics, Inc. (NASDAQ:MGNX) news
Every Macrogenics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
August 13, 2026
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
August 11, 2026
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
July 23, 2026
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
July 2, 2026
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
June 22, 2026
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
May 14, 2026
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
May 13, 2026
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
May 11, 2026
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
May 4, 2026
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
April 8, 2026
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
March 9, 2026
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
February 23, 2026
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
November 12, 2025
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
November 6, 2025
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
August 14, 2025
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
August 13, 2025
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
June 10, 2025
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
June 3, 2025
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
May 13, 2025
MacroGenics Announces Date of First Quarter 2025 Financial Results
May 6, 2025
MacroGenics to Participate in Upcoming Investor Conference
May 1, 2025
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
March 20, 2025
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
March 6, 2025
MacroGenics to Participate in Upcoming Investor Conferences
February 27, 2025
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
November 5, 2024
MacroGenics Announces Leadership Transition
October 30, 2024
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
October 29, 2024
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
October 22, 2024
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
September 8, 2024
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
August 6, 2024
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
July 30, 2024
MacroGenics Provides Vobramitamab Duocarmazine Update
July 30, 2024
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
May 9, 2024
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 3, 2024
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 3, 2024
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
March 7, 2024
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
February 27, 2024
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
November 6, 2023
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
October 31, 2023
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
September 5, 2023
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
August 9, 2023
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
July 31, 2023
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
May 9, 2023
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
May 4, 2023
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
March 22, 2023
MacroGenics Provides Corporate Update and 2022 Financial Results
March 15, 2023